Navigation Links
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
Date:12/7/2009

SAN DIEGO, Dec. 7 /PRNewswire/ -- Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

The open-label, dose-escalation study, "AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Phase I AML Study," was designed to evaluate the safety, tolerability, and pharmacokinetic profile of AC220 in AML patients with predominantly relapsed or refractory disease. AC220 was generally well-tolerated in AML patients, and importantly, there was no treatment-related mortality observed in this study. Clinical response and median survival were assessed as secondary endpoints and analyzed for the overall study population, in addition to patient subsets based on the presence or absence of the FLT3 genotype for the internal tandem duplication (ITD) mutation (FLT3 ITD+ and FLT3 ITD-, respectively). Following treatment with AC220, responses were observed in both FLT3 ITD+ and FLT3 ITD- patients, and responders in each group had at least a doubling in median survival versus non-responders.

"AML represents a challenging hematological malignancy to treat. A significant portion of AML patients have activating FLT3 mutations, and these patients have a particularly poor prognosis and are often refractory to current treatment options," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, and primary investigator for the Phase I Study. "These encouraging results with AC220 warrant further studies of this promising
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... , Dec. 23, 2014 In response to ... Association of Sierra Leone , Direct Relief ... for the treatment of local health workers who ... a new dedicated Ebola care center was constructed for foreign ... facility is not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... Pharmaceutical companies are dramatically increasing their investments ... demands of a patient-empowered, data-driven, outcomes-focused future in ... company investment in smart phone apps, educational websites, ... increased 78%, as companies embrace a role that ...
... Inc. (Nasdaq: MLAB ) today announced that ... cash dividend of 12 cents per share of common ... record at the close of business on February 25, ... markets electronic instruments and disposables for industrial, pharmaceutical and ...
Cached Medicine Technology:Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 2Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 3Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 4Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 5
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... 2014 “ SmileStix ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... stickers. , The old saying goes, “A picture says a ... that can describe a single image, because each picture holds ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... cause of death and disease in the U.S., with more ... consequences. And yet teens still smoke. Indeed, smoking usually begins ... smokers became hooked by the time they were 18. Meanwhile, ... While studies have linked cigarette smoking to deficits ...
... K. Ganguly, Distinguished Research Professor of Chemistry at ... Award Lecture at the University of Michigan. Named ... G. Topliss, the lectures were established to recognize ... and industrial scientists. Dr. Ganguly,s lecture, "Drug Discovery ...
... is the most frequently mutated in human cancer. It encodes ... acts primarily as a regulator of how genes are made ... of Medicine show that the protein has at least one ... one of body,s main sources of fuel. These new insights ...
... (HealthDay News) -- Epilepsy patients who are poor are ... and a lower overall quality of life compared to ... Poor patients also visit hospital emergency departments more often ... to lead author Dr. Charles E. Begley, professor of ...
... sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical ... tools in identifying this disease. According to a new ... Academy of Orthopaedic Surgeons (JAAOS), the rate of ... to screen for juvenile arthritis makes their value limited. ...
... has awarded Arizona State University (ASU) a $1 million ... Meldrum, Ph.D., at the Biodesign Institute. The team is ... called a "Cell-CT" scanner, that will perform functional computed ... technology will allow researchers to observe and assess the ...
Cached Medicine News:Health News:Tobacco smoking impacts teens' brains, UCLA study shows 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 3Health News:Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan 2Health News:Penn researchers find new role for cancer protein p53 2Health News:Penn researchers find new role for cancer protein p53 3Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: